Cristal L Brown1, Bradley G Hammill2, Laura G Qualls2, Lesley H Curtis3, Andrew J Muir1. 1. Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. 3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: lesley.curtis@duke.edu.
Abstract
CONTEXT: For end-stage liver disease (ESLD) patients, care focuses on managing the life-threatening complications of portal hypertension, causing high resource utilization. OBJECTIVES: To describe the end-of-life trajectory of hospitalized ESLD patients in Medicare. METHODS: Using a 5% random sample of Medicare fee-for-service beneficiaries, we performed a retrospective cohort study, identifying hospitalized ESLD and heart failure (HF) patients (2007-2011). Index hospitalization end points included mortality, discharge to hospice, and length of stay. Postdischarge end points included all-cause mortality, rehospitalization, hospice enrollment, and days alive and out of hospital (DAOH). Follow-up was at one and three years after index hospitalization discharge. A reference cohort of decompensated HF patients was used for baseline comparison. RESULTS: At one year, the ESLD cohort (n = 22,311) had 209 DAOH; decompensated HF (n = 85,397) had 252 DAOH. Among ESLD patients, inpatient mortality was 13.5%; all-cause mortality was 64.9%. For these outcomes, rates were higher in those with ESLD than HF. In the ESLD group, rehospitalization rate was 59.1% (slightly lower than the HF group), hospice enrollment rate was 36.1%, and there were higher than expected cancer rates. For hospice-enrolled patients, the median length of time spent in hospice was nine days. The HF cohort had lower hospice enrollment, but more days enrolled. CONCLUSION: The results of this study show that morbidity and mortality rates associated with end of life in ESLD are substantial. There is an acute need for alternative approaches to manage the care of ESLD patients.
CONTEXT: For end-stage liver disease (ESLD) patients, care focuses on managing the life-threatening complications of portal hypertension, causing high resource utilization. OBJECTIVES: To describe the end-of-life trajectory of hospitalized ESLD patients in Medicare. METHODS: Using a 5% random sample of Medicare fee-for-service beneficiaries, we performed a retrospective cohort study, identifying hospitalized ESLD and heart failure (HF) patients (2007-2011). Index hospitalization end points included mortality, discharge to hospice, and length of stay. Postdischarge end points included all-cause mortality, rehospitalization, hospice enrollment, and days alive and out of hospital (DAOH). Follow-up was at one and three years after index hospitalization discharge. A reference cohort of decompensated HF patients was used for baseline comparison. RESULTS: At one year, the ESLD cohort (n = 22,311) had 209 DAOH; decompensated HF (n = 85,397) had 252 DAOH. Among ESLD patients, inpatient mortality was 13.5%; all-cause mortality was 64.9%. For these outcomes, rates were higher in those with ESLD than HF. In the ESLD group, rehospitalization rate was 59.1% (slightly lower than the HF group), hospice enrollment rate was 36.1%, and there were higher than expected cancer rates. For hospice-enrolled patients, the median length of time spent in hospice was nine days. The HF cohort had lower hospice enrollment, but more days enrolled. CONCLUSION: The results of this study show that morbidity and mortality rates associated with end of life in ESLD are substantial. There is an acute need for alternative approaches to manage the care of ESLD patients.
Authors: J S Bajaj; L R Thacker; J B Wade; A J Sanyal; D M Heuman; R K Sterling; D P Gibson; R T Stravitz; P Puri; M Fuchs; V Luketic; N Noble; M White; D Bell; D A Revicki Journal: Aliment Pharmacol Ther Date: 2011-09-19 Impact factor: 8.171
Authors: Marilyn Kendall; Emma Carduff; Anna Lloyd; Barbara Kimbell; Debbie Cavers; Susan Buckingham; Kirsty Boyd; Liz Grant; Allison Worth; Hilary Pinnock; Aziz Sheikh; Scott A Murray Journal: J Pain Symptom Manage Date: 2015-03-28 Impact factor: 3.612
Authors: Jejo D Koola; Sam B Ho; Aize Cao; Guanhua Chen; Amy M Perkins; Sharon E Davis; Michael E Matheny Journal: Dig Dis Sci Date: 2019-09-17 Impact factor: 3.199
Authors: Nneka N Ufere; David L O'Riordan; Kara E Bischoff; Angela K Marks; Nwamaka Eneanya; Raymond T Chung; Vicki Jackson; Steven Z Pantilat; Areej El-Jawahri Journal: J Pain Symptom Manage Date: 2019-07-19 Impact factor: 3.612
Authors: John H Holden; Hani Shamseddeen; Amy W Johnson; Benjamin Byriel; Kavitha Subramoney; Yao-Wen Cheng; Akira Saito; Marwan Ghabril; Naga Chalasani; Greg A Sachs; Eric S Orman Journal: J Palliat Med Date: 2020-02-24 Impact factor: 2.947
Authors: Nneka N Ufere; Jennifer L Halford; Joshua Caldwell; Min Young Jang; Sunil Bhatt; John Donlan; Janet Ho; Vicki Jackson; Raymond T Chung; Areej El-Jawahri Journal: J Pain Symptom Manage Date: 2019-10-23 Impact factor: 3.612
Authors: Arpan Patel; Steven Asch; Anna Liza Antonio; Fasiha Kanwal; Karl Lorenz; Deborah Riopelle; Anna Dickey; Jennifer Larkin; Martin Lee; Anne Walling Journal: Dig Dis Sci Date: 2020-01-11 Impact factor: 3.199
Authors: Muhammad Irfan; Yasir Mahmud; Rana Muhammad Suhail Khan; Qamar Rafiq; Muhammad Arif Nadeem; Aftab Mohsin Journal: Pak J Med Sci Date: 2019 Sep-Oct Impact factor: 1.088
Authors: Roberta I Jordan; Matthew J Allsop; Yousuf ElMokhallalati; Catriona E Jackson; Helen L Edwards; Emma J Chapman; Luc Deliens; Michael I Bennett Journal: BMC Med Date: 2020-11-26 Impact factor: 8.775